|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2005-12-29
|
|
pubmed:abstractText |
Current chemotherapy regimens for breast cancer result in high incidences of anemia, which can be treated with erythropoietic agents. The relative efficacy of darbepoetin alfa and epoetin alfa was explored in this phase II, open-label, randomized, multicenter trial in anemic patients with breast cancer receiving chemotherapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1526-8209
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
6
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
446-54
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:16381629-Adult,
pubmed-meshheading:16381629-Aged,
pubmed-meshheading:16381629-Aged, 80 and over,
pubmed-meshheading:16381629-Anemia,
pubmed-meshheading:16381629-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16381629-Breast Neoplasms,
pubmed-meshheading:16381629-Drug Administration Schedule,
pubmed-meshheading:16381629-Erythropoietin,
pubmed-meshheading:16381629-Female,
pubmed-meshheading:16381629-Humans,
pubmed-meshheading:16381629-Middle Aged,
pubmed-meshheading:16381629-Patient Satisfaction,
pubmed-meshheading:16381629-Recombinant Proteins,
pubmed-meshheading:16381629-Treatment Outcome
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly.
|
|
pubmed:affiliation |
Northwest Medical Specialties, Tacoma, WA 98405, USA. mnelson@nwmedicalspecialties.com
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
